CMPS · CIK 0001816590 · operating
COMPASS Pathways plc is a biotechnology company developing psilocybin-based therapies for mental health conditions. The company's primary asset is COMP360, a formulated psilocybin therapy currently advancing through late-stage clinical development. COMP360 is in Phase III trials for treatment-resistant depression, the company's lead indication, with Phase II studies underway for post-traumatic stress disorder and anorexia nervosa.
The company operates primarily in the United States and United Kingdom, with its administrative headquarters in London. As of the latest available information, COMPASS Pathways employs 166 full-time staff. The organization was incorporated in 2020 following a name change from COMPASS Rx Limited in August of that year. The company's business model centers on the clinical development and potential commercialization of COMP360, with revenue generation contingent on regulatory approval and market launch of its lead therapeutic candidate.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.30 | $-2.30 | +0.9% | |
| 2023 | $-2.32 | $-2.32 | -7.4% | |
| 2022 | $-2.16 | $-2.16 | -20.7% | |
| 2021 | $-1.79 | $-1.79 | — |